Legend Biotech Corporation (LEGN)

Legend Biotech Corporation's Q·Score is 5.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $57.23 is 143% above current price. Key area to monitor: currently unprofitable (-29% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for LEGN is $57.23, based on ratings from 16 Wall Street analysts. This is 142.6% above the current price of $23.59. Price targets are forward-looking estimates and not guarantees of future performance.

Legend Biotech Corporation (LEGN) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 20.5×. The consensus analyst price target of $57.23 is 143% above the current price.

Legend Biotech Corporation is scheduled to report earnings in 9 days, on May 12, 2026.

Legend Biotech Corporation has a net profit margin of -28.8%, indicating the company is currently operating at a net loss. Its gross margin stands at 20.0%, reflecting a more cost-intensive business model.

Legend Biotech Corporation is reporting strong year-over-year growth of 64.2%.

Legend Biotech Corporation has a debt-to-equity ratio of 0.41×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.96×, indicating comfortable short-term liquidity.